Determination of Perazine Serum Levels by Gas Liquid Chromatography under Clinical Routine Conditions by Schley, J. et al.
Schley, Ried el and Müller-Oerlinghausen: Determination of perazine serum levels by gas liquid chromatography 307
J. Clin. Chem. Clin. Biochem.
Vol. 16,1978, pp. 307-311
Determination of Perazine Serum Levels by Gas Liquid Chromatography under Clinical Routine
Conditions
By/. Schley,E. Riedel, and Ä Müller-Oerlinghausen
Institute of Biochemistry and Department of Psychiatry, Free University of Berlin
(Received September 13,1977/January 18,1978)
Summary: A quantitative gas liquid Chromatographie method for the determination of serum levels of perazine
(10-[3'-(r/-methyl-4"-piperazinyl)-propyl]-phenothiazine) is described. Perazine is used as a neuroleptic drug.
The main problem consists in optimizing the Chromatographie system. A sensitivity of appr. 60—150 nmol/1
(20—50 Mg/1) serum is achieved. Examples of optimization, analyses with patient samples, and the reproducibility
of the results are presented.
Gasliquidchromatographische Bestimmung der Perazin-Konzentration im Serum unter klinischen Routine-
bedingungen
Zusammenfassung: Es wird eine quantitative gasliquidchromatographische Methode zur Bestimmung von Perazin
(lO-tS^ril'^Methyl-^'-piperazinyl^propylj-phenothiazin) im Serum beschrieben. Perazin wird als Neuroleptikum
eingesetzt. Das methodische Hauptproblem ist die Optimierung des chromatographischen Systems, wodurch eine
Empfindlichkeit bis zu 59—148 nmol/1 (20—50 Mg/1) erreicht wird. Reproduzierbarkeit und praktische Anwendbarkeit
unter klinischen Bedingungen werden dargestellt.
Introduction
The quantitative determination of perazine (10-[3f-
(1 "-methyl·4"-pipe azinyl)-propyl]-phenothiazine *)
in human serum samples under clinical routine con-
ditions presents an analytical problem which has not
yet found a satisfactory solution. Therapeutic serum
levels of perazine can be expected to be within the
range of approx. 59-885 nmol/1 (20-300 Mg/l) (1).
Spectrophotometric and fluorometric methods are
unsuitable, owing to the codeterminatipn of meta-
bolites (2, 3). The Chromatographie separation of serum
eluates is an indispensable prelude to the detection
step, but this entails a loss of material and reduced
sensitivity. The autoxidability of the phenothiazines
provides1 additional analytical problems.
Breyer & Villumsen (1) have developed a direct densito.
metric thin layer Chromatographie method, which has
been shown to be very sensitive but also rather time-
consuming (4). The use of gas liquid chromatography
(GLC) entails some special difficulties, which are
r) Taxilan, Promonta, D-2000 Hamburg 26
described in detail below. The very sensitive electron
capture detectors, which have been used for determina-
tion of phenothiazine derivatives such as chlorpromazine
or perphenazine, cannot be applied in the case of perazine.
For the determination of 20—50 ng perazine by use of
the FID, however, the analytical procedure must be fully
optimized. In the method published recently by Vander-
heeren et al. (5) most of the steps are not optimized, so
that determinations are^limited to samples containing from
1.47 nmol (= 100 Mg/1 serum with 5 ml serum extracted)
upwards. It is, however, possible, to perform 20 GLC de-
terminations of perazine daily per column with a lower
detection limit of 59 nmol/1 (20 Mg/1), providing the




All reagents were Merck p.a. quality. Siliconc XE 60, Silicone
OV-12, dichlormethylsilane, Chromosorb G and Gaschrome
Q 80/100; 100/120 mesh were ordered from WGA-Düsseldorf.
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Procedure
Preparation of glass vessels
Cleaning of all glass vessels should be done without detergents.
All glass vessels, after being cleaned with hot water, are boiled
in about 6 mol/1 HC1, rinsed with double distilled water, dried,
and treated with 50 ml/1 dichloromethane in toluene. They are
dried finally at 120°C for 1 hour.
Extraction
5 ml serum (deep frozen at -15°C and thawed shortly before
processing) with addition of 1 ml of 1 mol/1 NaOH are kept in
a boiling water bath for 15 min, then cooled down to room
temperature and extracted 3 times with 5 ml w-heptane. The
combined extracts are evaporated at room temperature or with
light heating (not > 35°C) under nitrogen.
Analysis
GLC was performed with a Varian 15 20 B using flame Ionisation
detectors. Column: glass, 190 cm, 4 mm φ, silanized, packed with
3% silicone OV-17 on Gaschrome Q 100/120 mesh. Injection
port: 270°C detector: 300°C. Oven: 270°C. Carrier gas'flow 30 ml
N2/min. H2: 30 ml/min. Air: 300 ml/min. Attenuation 2 or
4 X 10~n. The evaporated heptane extracts are taken up with
25 μΐ standard solution (internal standard: 48.46 nmol/1
stigmasterol in ethanol); they must be kept cool at 0-4°C and
tightly closed until injection. After careful stirring with a
spatula 1 μΐ is injected. The column is checked daily by running




We investigated the distribution coefficients and elution
characteristics of the following solvents: Methylene
dichloride, chloroform, ethylene dichloride, benzene,
toluene, Η-heptane, w-heptane/isoamyl alcohol (985 ml
+ 15 ml) in relationship to the pH of the aqueous phase
(4). w-heptane was found to be the most suitable solvent
for the GLC procedure: at pH 10.4 the distribution co-
efficient was 5.7 and the coextraction of serum factors
was the lowest with regard of the temperature range used
for perazine detection (fig. 1 a). Sufficiently low solubi-
lity of perazine base in water is achieved in an alkaline
milieu, i.e. pH 8.5. Short heating of the alkalinized
serum samples in a boiling water bath results in a better
separation of the organic and the aqueous phase without
loss of the drug (tab. 1). Inactivation of the surface
of the glass vessels e.g. by silanization leads to con-
siderably increased recovery values. The use of detergents
for cleaning of the test tubes etc. must be avoided under
any circumstances. Precleaning is done best by boiling
with about 6 mol/1 hydrochloric acid.
Optimization of the GLC system
As stationary phases we have examined silicone^XE-60
and silicone-OV-17 (3%) on Chrornosorb G or Gas-
chrome Q (80/100 or 100/120 mesh resp.). Resolution
with the 80/100 mesh supports was lower and the loss
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Fig. 1. Gas chromatqgram (different series at different days),
la: Blank serum
Ib: Perazine/stigmasterol in ethano c solution on 3%
silicone-OV-17 (Gaschrome Q, 100/120 mesh)
Attenuation 8 X 10~12 As
1 c: Serum of a patient treated with perazine
Attenuation 8 X 10~i? As
Tab. 1. Recovery of perazine extracted from aqueous standard







solution From spiked sera
No treat- Heated Heated 15 min







10 94 8 90 5 52 8 76
15 86 7 89 6 53 6 73
16 88 6 89 4 59 6 72
sorbents. The most suitable stationary phase proved
to be 3% silicone-OV-17 on Gaschrome Q 100/120
mesh. Optimization is achieved by determination of
the Van Deemter hyperbolic function which relates the
column efficiency - expressed as height equivalent to a
theoretical plate (HETP) - to carrier gas flow changes;
in addition, peak height, peak area and retention time
were taken into consideration (fig. 2). Measurements
were performed with standard solutions of 2.95
mmol/1 perazine in ethanol. The aim is to find the
carrier gas flow rate at minimal retention time (in
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Fig. 2. Column efficiency (height equivalent to a theoretical
plate HETP ο—ο), peak height (o o), peak area
(o o) and retention time (x—x) as a function of
carrier gas flow (N2>- Analyses were performed with
2.95 nmoi perazine. Technical data ref. text.
order to increase the laboratory capacity) and at
maximum peak height or area (in order to increase
the sensitivity). From figure 2 it can be seen that it is
not reasonable to make use of the highest possible sepa-
ration performance (achieved at u = < 10 ml/min),
because then the peak height is too small and retention
time too long. On the other hand, it does not make
much sense to increase the carrier gas flow beyond
u = 30 ml/nun, because this does not result in a
substantial reduction of the retention time, but in a
considerable loss of sensitivity. Figure 2 shows that
the optimal carrier gas flow for highest sensitivity
and shortest retention time is 30 ml/min. Another
variable to be optimized is the column temperature.
With increasing column temperature, peak heights are
elevated and retention times shortened (fig. 3),
thereby leading to an improved sensitivity and
increased analytical capacity. If the full sensitivity
of the Chromatographie system is used the perazine
Tab. 2. Optimization of the GLC system.
Technical data ref. text. Analyses were performed with
2.95 nni l perazine.
u = carrier gas flow; t^ = retention time
P = peak height; A = peak area; HETP = 1000 1/N
(1 = column length (m); N = number of theoretical plates
= 16 fah with W - peak width (min).
















































peak comes within the tailing of the solvent peak
(at column temp. > 250°C); electronic integration tech-
niques are, therefore, not recommended. The quantita-
tive evaluation should be done by comparison of the
peak heights with those of an internal standard.
Reproducibility
Once the optimal values for the carrier gas flow and the
column temperature have been determined, their daily
control is essential for routine analytical work. This can
be best achieved by setting up a calibration curve before
every course of analysis. 29, 59, and 118 nmol (= 10, 20,
or 40 μg, resp.) perazine were used with 48.46 nmol/1
stigmasterol as internal standard (fig. 4). The evaluation
by comparison of the peak heights does not give a linear
calibration curve in all cases. The correct ratio between
perazine and stigmasterol concentration in the solvent
must be carefully checked. Evaporation of the solvent
leads to a higher concentration and thereby to changes
of the peak height ratio which may result into evaluation
errors. Figure 5 shows the decrease of the peak height
ratios with increasing concentration of perazine and
stigmasterol in the ethanolic solution (at always the same
concentration ratio 1:1). Therefore, extracts which have
been taken up with the standard solution should be
kept cool (0—4°C) and analysed the same day.
The recovery and the analytical error of analyses ob-
tained with perazine-spiked blank sera can be seen from
table 3. The quantitative evaluation of perazine deter-
minations in serum is done by referring to the daily cali-
bration curve and multiplication with the correction
















Fig. 3. Retention time ( ) and peak height ( ) of pera-
zine (·) and stigmasterol (o) as a function of the column
temperature. Technical data ref. text.
J. Clin. Cheni. Clin. Biochem. / Vol. 16, 1978 / No. 5







Fig. 4. Perazine calibration curve using peak height comparison








Fig. 5. Peak height ratio (ref. fig. 4) as a function of the con-
centration of perazine and stigmasterol (1:1) in the
ethanolic solution.
Tab. 4. Reprodücibility of perazine determinations in serum
samples of 14 out-patients. Each sample was analyzed
twice (I-II) within 5-8 days.
Patient Pera- Pera-
zine I zine II
[nmol/1] [nmol/1]
Patient Pera- Pera-












































Tab. 5. Retention time (tR), peak height (P) and relative peak

















between the double determination was 17.38 nmol/1
corresponding to a ratio of 0.065 between mean
difference and mean value (tab. 4). The precision
within one day was determined as VK = 2.55 % (N = 6;
=s 364.3 nmol/1; different extractions of one pooled
sample). Relative retention time was 0.59.
Specificity
The retention time of the following psychotropic com-
pounds were determined and it was found that they do
not interfere with the perazine measurement: buta^
perazine, trifluoperazine, levömepromazine, chlor-
promazine, haloperidol, imipramine, arnitriptyline, nor-
tryptiline.








































examined by analysing the same serum samples twice, i.e.
14 samples which were split immediately after collecting
the blood and processed independently of each other
within an interval of 5—8 days. The mean difference
Concluding remarks
The lowest detection limit of the method as described
above is appr. 60 nmol/1. A clinical study which should
demonstrate the practicability of the method under
routine conditions, i.e. in perazine treated out-patients,
has just been finished (6). Two main metabolites, des-
methylperazine and perazine sulfoxide cannot be deter-
mined together with perazine in human sera. Perazine,
desmethylperazine, and perazine sulfoxide are well sepa-
rated from each other by this GLC procedure; however,
the retention time of desmethylperazine is the same as
that of a serum lipid peak, and the sensitivity of the
system for the sulfoxide is about 6 times lower than
for perazine.
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An independent GLC method for the determination
of perazine in body fluids is thus available, in addition
to the TLC method quoted above, thus providing the pre-
requisite for a systematic comparative control of these
two clinical methods. Such internal comparative control
by two independent methods appears to us much more
relevant than the quality control by multicentered
studies, which may result in a better comparability of
the results of different laboratories, but which cannot
exclude systematic analytical errors in the case of
methods not yet standardized. The comparative study
ofRichens (7) provides much evidence for this argument.
As the determination of neuroleptics or antidepressant
drugs in human sera requires at least a 100 times higher
analytical sensitivity than in the case of anticonvulsant
drugs, a rigid and comparative control of the methods
is essential.
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